This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Verastem Up on Positive Data From Early-Stage Copiktra Study
by Zacks Equity Research
Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.
Dow on Pace for Best June: 5 Blue Chip Stocks to Buy
by Tirthankar Chakraborty
Dow eyes best June in 80 years as investors cheer the Fed's shift to a more dovish stance.
Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval
by Zacks Equity Research
Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.
Sanofi/Regeneron's Asthma Candidate Meets Goal in Study
by Zacks Equity Research
Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.
Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma
by Swarup Gupta
The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.
Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
by Kinjel Shah
Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.
Are You Looking for a Top Momentum Pick? Why Merck (MRK) is a Great Choice
by Zacks Equity Research
Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Stock Market News For Jun 20, 2019
by Zacks Equity Research
Wall Street closed higher on Wednesday after the Fed kept the federal fund target rate unchanged.
AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod
by Zacks Equity Research
AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.
Merck's Keytruda Gets 2nd Label Expansion Approval in June
by Zacks Equity Research
Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $84.45 in the latest trading session, marking a +1.38% move from the prior day.
Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients
by Zacks Equity Research
Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
by Zacks Equity Research
AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
Bayer to Invest 5 Billion Euros in Weedkiller Research
by Zacks Equity Research
Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.
J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
by Zacks Equity Research
J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.
Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
by Zacks Equity Research
Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.
Agilent Announces Receipt of FDA Approval for pharmDX Assay
by Zacks Equity Research
Agilent (A) receives approval on the expanded use of its PD-L1 IHC 22C3 pharmDx assay.
3 Big Pharma Stocks to Buy Right Now
by Zachary Stutler
These big pharma stocks all have a Zacks Rank #2 or better.
Dow 30 Stock Roundup: United Technologies-Raytheon Merger, Merck's Tilos Buyout
by Swarup Gupta
The index traversed a volatile week, guided largely by trade-related developments.
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
by Kinjel Shah
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230
by Zacks Equity Research
Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.
Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock
by Zacks Equity Research
Here are five reasons why investors may consider betting on Merck (MRK) stock
Novartis Reports Data on Cosentyx for Psoriatic Arthritis
by Zacks Equity Research
Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.